Approved In China 2026
Ecnoglutide
Also known as XW003
At a glance
- What it is
- cAMP-biased GLP-1 agonist approved in China, appearing in gray-market channels.
- Evidence
- Clinical trialsHow the tiers workThe BMJ network meta-analysis groups ecnoglutide with mazdutide and retatrutide in a 13.1–14.6% weight-loss band, at very low to low certainty, meaning the effect estimate could move substantially with further evidence. Why this tier
- Routes
- Subcutaneous
- Category
- Metabolic
- WADA
- We do not state a status
Putting Ecnoglutide on a schedule, with the vial it comes from and a log of each dose, happens in the app: Claritide for iPhone.
Why this tier
The BMJ network meta-analysis groups ecnoglutide with mazdutide and retatrutide in a 13.1–14.6% weight-loss band, at very low to low certainty, meaning the effect estimate could move substantially with further evidence. It is also in study for adolescents, for obesity with obstructive sleep apnoea, and for obesity with knee osteoarthritis. There is no US label.
What it is
Ecnoglutide is a cAMP-biased GLP-1 receptor agonist from Sciwind Biosciences, given once weekly by subcutaneous injection with an oral tablet in development. China approved it in January 2026 for glycaemic control in type 2 diabetes and in March 2026 for long-term weight management. It is not FDA-approved and has no US label.
How it works
Ecnoglutide is described as cAMP-biased: it preferentially engages the cAMP signalling arm downstream of the GLP-1 receptor rather than the beta-arrestin arm. The claimed advantage of biased agonism is less receptor internalisation and therefore more sustained signalling. The clinical relevance of that bias, as against the ordinary GLP-1 effects of appetite suppression, delayed gastric emptying and glucose-dependent insulin release, is not something the published outcome data separates out.
Commonly researched ranges
- Obesity Phase 3 arms (SLIMMER)1.2–2.4 mg
Three arms and nothing between them: 1.2, 1.8 and 2.4 mg weekly. 1.2 and 1.8 are the published figures and are not rounded here. This is the ladder behind the March 2026 Chinese approval for weight management.
- Type 2 diabetes escalation (EECOH-1)0.3–1.2 mg
A different indication and a different ladder. Kept separate on purpose: the diabetes escalation tops out where the obesity ladder starts.
| Phase | Amount | Frequency | Timing | Note |
|---|---|---|---|---|
| Obesity Phase 3 arms (SLIMMER) | 1.2–2.4 mg | Once weekly for 48 weeks | Not established in available literature | Three arms and nothing between them: 1.2, 1.8 and 2.4 mg weekly. 1.2 and 1.8 are the published figures and are not rounded here. This is the ladder behind the March 2026 Chinese approval for weight management. |
| Type 2 diabetes escalation (EECOH-1) | 0.3–1.2 mg | Once weekly, escalated 0.3 → 0.6 → 1.2 mg | Not established in available literature | A different indication and a different ladder. Kept separate on purpose: the diabetes escalation tops out where the obesity ladder starts. |
- Cycle guidance
- Not established in available literature
- Goals
- Fat loss
Where this sits with the FDA
Approved in China and not FDA-approved, with no US label. Material reaching the US through international gray-market channels has no US regulatory oversight of any kind.
Last change · 1 March 2026 · China approved ecnoglutide for long-term weight management in March 2026, following approval for type 2 diabetes in January 2026; our sources do not give exact days.
Primary sourceWADA status
Not named on the 2026 Prohibited List. We could not determine a classification and do not state one.
We looked and could not resolve it. This is not the same as "not prohibited". Treat it as unresolved and check with your federation before competing.
Mixing recipes our sources document
Not established in available literature. Use the calculator with the figures printed on your own vial.
Open the calculator
Week by week
Not established in available literature.
Side effects
Not established in available literature. Absence from this page does not mean absence of risk. It means our sources publish no side-effect profile for Ecnoglutide.
Contraindications and interactions
Do not use if
Not established in available literature.
Interactions
Not established in available literature.
Absence from this list does NOT mean safety. It means lack of research.
Storage and cost
- Storage
- Our sources publish no reconstitution or storage protocol for ecnoglutide.
- Cost
- Not established in available literature
Ecnoglutide in full
Limited coverage
Ecnoglutide (XW003) is a cAMP-biased GLP-1 receptor agonist from Sciwind Biosciences. Once weekly, subcutaneous, with an oral tablet in development.
Approved in China in January 2026 for glycaemic control in type 2 diabetes, and in March 2026 for long-term weight management in adults with obesity, or overweight plus at least one comorbidity. Not FDA-approved, no US label.
Where it sits
The BMJ network meta-analysis of the whole weight-loss class groups ecnoglutide with mazdutide and retatrutide in a 13.1 to 14.6% weight-loss band, at very low to low certainty.
That certainty rating is the part worth reading. It means the estimate rests on limited or indirect evidence and could move substantially as more data arrives. A number in the same band as a better-evidenced drug is not the same claim as a number with the same confidence behind it.
Further studies are running in adolescents, in obesity with obstructive sleep apnoea, and in obesity with knee osteoarthritis.
It is here because approval in one large market is how compounds start appearing in international gray-market channels, and because a US buyer sourcing it that way gets neither the Chinese regulatory oversight nor the American kind.
Sources
- 1BMJ network meta-analysis of weight-loss agents, 2026
- 2Lancet Diabetes & Endocrinology · SLIMMER Phase 3, the 1.2 / 1.8 / 2.4 mg weekly obesity arms (dose review, 2026-08-17)
- 3EECOH-1 · the type 2 diabetes escalation, 0.3 → 0.6 → 1.2 mg weekly (dose review, 2026-08-17)
- 4Sciwind Biosciences · NMPA approval for chronic weight management, 6 March 2026 (dose review, 2026-08-17)
Every record in this library is free to read, and it stays free. Your own schedule, vials and log live in the app: Claritide for iPhone.